Author:
Gansevoort Ronald T.,Hariri Ali,Minini Pascal,Ahn Curie,Chapman Arlene B.,Horie Shigeo,Knebelmann Bertrand,Mrug Michal,Ong Albert C.M.,Pei York P.C.,Torres Vicente E.,Modur Vijay,Antonshchuk Igor,Perrone Ronald D.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral AL01211 in Healthy Chinese Volunteers;Clinical Drug Investigation;2024-05-02
2. Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights;Expert Opinion on Investigational Drugs;2024-04-21
3. Phase 1 Healthy Volunteer Study of AL01211, an Oral, Non‐brain Penetrant Glucosylceramide Synthase Inhibitor, to Treat Fabry Disease and Type 1 Gaucher Disease;Clinical Pharmacology in Drug Development;2024-02-16
4. Abdominal Imaging in ADPKD: Beyond Total Kidney Volume;Journal of Clinical Medicine;2023-08-05
5. Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial;The Lancet Neurology;2023-08